Pharmacokinetics and pharmacodynamics of growth hormone-releasing peptide-2: a phase I study in children.

Pihoker C, Kearns GL, French D, Bowers CY

The Journal of clinical endocrinology and metabolism1 Apr 1998Cited by 17 (Europe PMC)

PMID9543135DOI10.1210/jcem.83.4.4744PepBankPUB-09543135

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. 4 results from people.

01HumanNon-randomized trialPharmacokinetics
In prepubertal children with short stature, a single intravenous 1 microg/kg dose of GHRP‑2 gave a terminal half-life of 0.55 h, Cmax of 7.4 ng/mL and clearance of 0.66 L/h x kg.
In plain wordsIn short children, GHRP‑2 given into a vein was cleared from the blood quickly, with a half-life of about half an hour.
Peptide
GHRP-2
Outcome
Not applicableGHRP-2 pharmacokinetics
Study
n = 10
Outcome group
Pharmacokinetics · Pharmacology
Studied dose
1 microg/kg · intravenous · single dose over 1 minAs given in this study (human).
Measurements
alpha
13.4 h(-1)
GHRP-2
beta
1.3 h(-1)
GHRP-2
t1/2beta
0.55 h
GHRP-2
AUC(0-infinity)
2.02 ng/mL x h
GHRP-2
Cmax
7.4 ng/mL
GHRP-2
plasma clearance
0.66 L/h x kg
GHRP-2
apparent volume of distribution
0.32 L/kg
GHRP-2
Source sentences
Summary
GHRP-2 PK parameters (mean +/- SD) were: alpha = 13.4 +/- 9.7 h(-1), beta = 1.3 +/- 0.3 h(-1), t(1/2beta) = 0.55 +/- 0.14 h, AUC(0-infinity) = 2.02 +/- 1.37 ng/mL x h, Cmax = 7.4 +/- 3.8 ng/mL, plasma clearance = 0.66 +/- 0.32 L/h x kg, and apparent volume of distribution = 0.32 +/- 0.14 L/kg.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten prepubertal children (nine boys and one girl; 7.7 +/- 2.4 yr old) received a single 1 microg/kg i.v. dose of GHRP-2 over 1 min, followed by repeated (n = 9) blood sampling over 2 h.
Report a problemFND-0954313501
02HumanNon-randomized trialPharmacokinetics
After a single intravenous GHRP‑2 dose in children with short stature, plasma GH reached a Cmax of 50.7 ng/mL at a Tmax of 0.42 h.
In plain wordsIn short children, one GHRP‑2 dose raised growth hormone in the blood to a peak within the first hour.
Peptide
GHRP-2
Outcome
Not applicableGH pharmacokinetics after GHRP-2
Study
n = 10
Outcome group
Pharmacokinetics · Endocrine and hormones
Studied dose
1 microg/kg · intravenous · single dose over 1 minAs given in this study (human).
Measurements
appearance rate constant
5.9 h(-1)
GH
elimination t1/2
0.37 h
GH
lag time
0.05 h
GH
Cmax
50.7 ng/mL
GH
Tmax
0.42 h
GH
AUC(0-infinity)
47.9 ng/mL x h
GH
Source sentences
Summary
PK parameters for GH were: appearance rate constant = 5.9 +/- 3.1 h(-1), elimination t(1/2) = 0.37 +/- 0.15 h, lag time = 0.05 +/- 0.01 h, Cmax = 50.7 +/- 17.2 ng/mL, Tmax = 0.42 +/- 0.16 h, and AUC(0-infinity) = 47.9 +/- 26.1 ng/mL x h.
1 context sentence(design, population, supporting numbers)
Summary · context
Ten prepubertal children (nine boys and one girl; 7.7 +/- 2.4 yr old) received a single 1 microg/kg i.v. dose of GHRP-2 over 1 min, followed by repeated (n = 9) blood sampling over 2 h.
Report a problemFND-0954313502
03HumanNon-randomized trialActivity measurement
A sigmoid Emax model of plasma GH after GHRP‑2 in children with short stature gave an EC50 of 1.09 ng/mL and an Emax of 67.5 ng/mL.
In plain wordsIn short children, a model linked the GHRP‑2 level in blood to the growth hormone rise it caused.
Peptide
GHRP-2
Outcome
Not applicableGHRP-2 pharmacodynamic parameters for GH
Study
n = 10
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microg/kg · intravenous · single dose over 1 minAs given in this study (human).
Measurements
Ke0
1.13 h(-1)
GHRP-2
gamma
13.15
GHRP-2
E0
6.63 ng/mL
GH
Emax
67.5 ng/mL
GH
EC50
1.09 ng/mL
GHRP-2
Source sentences
Summary
PD parameters for GHRP-2 were: Ke0 = 1.13 +/- 0.94 h(-1), gamma = 13.15 +/- 9.44, E0 = 6.63 +/- 4.86 ng/mL (GH), Emax = 67.5 +/- 23.5 ng/mL (GH), and EC50 = 1.09 +/- 0.59 ng/mL.
2 context sentences(design, population, supporting numbers)
Summary · context
PD parameters were generated using the sigmoid Emax model.
Summary · context
Ten prepubertal children (nine boys and one girl; 7.7 +/- 2.4 yr old) received a single 1 microg/kg i.v. dose of GHRP-2 over 1 min, followed by repeated (n = 9) blood sampling over 2 h.
Report a problemFND-0954313503
04HumanNon-randomized trialEfficacy outcome
In children with short stature, GHRP‑2 produced a significant increase in plasma GH concentrations compared with pretreatment values.
In plain wordsIn short children, GHRP‑2 raised growth hormone in the blood compared with before treatment.
Peptide
GHRP-2
Outcome
IncreasePlasma GH increase after GHRP-2
Study
n = 10
Comparator
Pretreatment values
Outcome group
Growth hormone and IGF-1 · Endocrine and hormones
Studied dose
1 microg/kg · intravenous · single dose over 1 minAs given in this study (human).
Source sentences
Summary
GHRP-2 produced a predictable and significant (i.e. compared to pretreatment values) increase in plasma GH concentrations
1 context sentence(design, population, supporting numbers)
Summary · context
Ten prepubertal children (nine boys and one girl; 7.7 +/- 2.4 yr old) received a single 1 microg/kg i.v. dose of GHRP-2 over 1 min, followed by repeated (n = 9) blood sampling over 2 h.
Report a problemFND-0954313504

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

Version 2Current
13 Oct 2026, 21:44 UTC
Study results updated
Version 1
13 Oct 2026, 16:31 UTC
First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

MeSH terms

PepBank is a research reference. Talk to a doctor before you use any peptide.